Novozymes Financial Statements From 2010 to 2024

NVZMY Stock  USD 59.38  1.92  3.34%   
Novozymes financial statements provide useful quarterly and yearly information to potential Novozymes AS investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Novozymes financial statements helps investors assess Novozymes' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Novozymes' valuation are summarized below:
Novozymes AS does not presently have any fundamental ratios for analysis.
Check Novozymes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novozymes' main balance sheet or income statement drivers, such as , as well as many indicators such as . Novozymes financial statements analysis is a perfect complement when working with Novozymes Valuation or Volatility modules.
  
This module can also supplement various Novozymes Technical models . Check out the analysis of Novozymes Correlation against competitors.

Novozymes AS Company Return On Equity Analysis

Novozymes' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Novozymes Return On Equity

    
  0.28  
Most of Novozymes' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Novozymes AS has a Return On Equity of 0.2789. This is 69.35% lower than that of the Basic Materials sector and 95.26% lower than that of the Specialty Chemicals industry. The return on equity for all United States stocks is 189.97% lower than that of the firm.

Novozymes AS Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Novozymes's current stock value. Our valuation model uses many indicators to compare Novozymes value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novozymes competition to find correlations between indicators driving Novozymes's intrinsic value. More Info.
Novozymes AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about  0.38  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novozymes AS is roughly  2.63 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novozymes by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novozymes' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Novozymes Financial Statements

Novozymes investors use historical fundamental indicators, such as Novozymes' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novozymes. Please read more on our technical analysis and fundamental analysis pages.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novozymes Pink Sheet Analysis

When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.